What Is in an Allergy Shot? Concentration Progression Explained

Colored vial labeling systems — silver, green, blue, yellow, red, or equivalent numbered sequences like #4 through #1 — indicate the allergen concentration level in your treatment series. The most dilute vial (silver or #4) contains the lowest allergen protein concentration, typically 1:10,000 v/v or 1:1,000 v/v depending on the starting protocol. Each subsequent vial represents approximately a 5–10x increase in concentration. The most concentrated vial (red or #1) is your maintenance concentrate — the full therapeutic dose. Not all practices use the same color-coding system, so confirm what your specific system means with your allergy nurse. What matters clinically is the relative position in your series, not the specific color.

Starting a new batch of your maintenance vial — when your current vial expires or is replaced — is a standard procedural moment that many allergists handle with a precautionary dose reduction. Even when a new vial is prepared from the same recipe as the previous one, batch-to-batch variability in allergen extract potency is possible, particularly for non-standardized extracts. Some practices routinely reduce the first injection from a new vial by 25–50% as a safety measure. Others maintain the dose unchanged if there is no reason to suspect a potency difference. Ask your allergy nurse or physician about their specific protocol for new vials, and report any reaction that feels different from your usual response after switching to a new vial.

The gradual dose escalation in allergy shots serves a specific immunological safety purpose: it prevents the systemic allergic reactions that would occur if too much allergen were introduced too quickly. Starting with an ultra-dilute dose allows the immune system to begin producing IgG4 blocking antibodies at a low, manageable allergen concentration. As blocking antibodies accumulate, the threshold for triggering a full allergic reaction rises, allowing the next dose increment to be safely tolerated. If this escalation were rushed, each injection would trigger the very allergic response the treatment aims to prevent. The gradual buildup is not about convenience — it is the core safety mechanism that makes immunotherapy possible for patients sensitized to potentially dangerous allergen concentrations.

Some patients cannot tolerate the standard maintenance concentration due to large local reactions or systemic responses at higher doses. This is more common in highly sensitized patients and those with certain allergen types. Allergists have several options: dose reduction within the current vial (staying at a lower volume rather than advancing to 0.5 mL), staying at a submaximal concentration permanently (maintenance at a lower concentration than the standard target), or adjusting the build-up schedule to advance more slowly. Research indicates that even submaximal doses are therapeutically effective — the clinical benefit is reduced compared to full maintenance dose, but not eliminated. If you experience significant reactions at higher doses, discuss dose-limited maintenance options with your allergist rather than stopping treatment entirely.

Yes — allergy shot extracts have a finite shelf life and must be replaced periodically. Glycerinated maintenance-concentration extracts maintain potency for approximately 1 year when stored at 2–8°C. More dilute aqueous build-up vials degrade faster, particularly at lower concentrations where protein adsorption to vial walls becomes significant. Your allergist's office should track expiration dates and prepare new vials before your current ones expire. If extract is stored improperly — exposure to heat during transport, inadequate refrigeration — potency degrades faster than expected. If you travel between offices for your injections, ensure your vials are transported under appropriate cold-chain conditions. Temperature-degraded extract may be less effective, and there is no reliable way to assess potency loss visually.

Yes — if allergy testing identifies new clinically significant sensitizations during your immunotherapy course, your allergist may reformulate your extract to include the new allergens. However, simply developing new IgE reactivity on a blood test does not automatically warrant adding it to your extract. Your allergist will consider whether the new sensitization is clinically relevant (producing symptoms), whether the new allergen is causing significant additional morbidity, and whether the benefit of adding it outweighs the complexity of reformulating and potentially restarting part of the build-up process. In practice, new significant sensitizations identified after the first year or two of maintenance are often handled case by case, and many allergists recommend completing the current course before reformulating.